Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Betahistine + oxybutynin crossover study in obstructive sleep apnoea
ACTRN12621000158864Phase 2Completed
- Sponsor
- Flinders University
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of betahistine and oxybutynin in obstructive sleep apnea hypopnea syndrome (OSAHS) (2 arms), sponsored by Flinders University. Primary endpoint: Apnoea/hypopnoea index. Started Feb 2021; status: completed.
02
Drugs
betahistineoxybutynin
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on ACTRN12621000158864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000158864.